In a bid to strengthen its medicines arm, Fresenius Kabi announced two deals on the same day - the acquisition of Akorn, a sterile injectables specialist in a deal worth US$4.3 B and the acquisition of Merck KGaA’s biosimilar portfolio for US$700 M. The Akorn deal expands Fresenius’ injectables business and its foray into new dosage forms, whereas the Merck acquisition will give the company a foothold in the biosimilar market.